Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies

Current Cancer Drug Targets

Volumn 11, Issue 9, 2011, Pages 1005-1024

  Podar, K ^a,b   Anderson, K C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

596; AMG 386; AVE8062; Axitinib; Bevacizumab; CDP860; CE 245677; CEP 11981; Cilengitide; Combretastatin; CP 868; Enzastaurin; Exherin; HUMV833; Lenalidomide; Metronomic chemotherapy; MN 029; OMP 21m18; Pazopanib; PF 4856884; Pomalidomide; REG421; Semaxanib; Sorafenib and sunitinib; TB403; Thalidomide; TZT 1027; Vadimezan; Vandetanib; Vatalanib; VEGF trap; VEGFR antibodies; ZD6126

Indexed keywords

3 (4 BROMO 2,6 DIFLUOROBENZYLOXY) 5 [3 [4 (1 PYRROLIDINYL)BUTYL]UREIDO] 4 ISOTHIAZOLECARBOXAMIDE; AFLIBERCEPT; AMG 386; AXITINIB; BEVACIZUMAB; BORTEZOMIB; BRIVANIB ALANINATE; CARBOPLATIN; CDP 860; CE 245677; CEP 11981; CILENGITIDE; CISPLATIN; CP 868596; CVX 060; D 6126; DENIBULIN; DEXAMETHASONE; DOCETAXEL; ENZASTAURIN; ETOPOSIDE; EVEROLIMUS; FLUOROURACIL; GEMCITABINE; HUMV 833; ICRUCUMAB; INTEDANIB; IRINOTECAN; LAPATINIB; LENALIDOMIDE; MELPHALAN; MONOCLONAL ANTIBODY; OMBRABULIN; OMP 21M18; PACLITAXEL; PAZOPANIB; PF 4856884; PLINABULIN; POMALIDOMIDE; RAMUCIRUMAB; REG 421; SAR 153192; SEMAXANIB; SOBLIDOTIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VATALANIB;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ALOPECIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BLEEDING; BLOOD CLOT LYSIS; BRAIN TUMOR; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM TUMOR; CHONDROSARCOMA; COLORECTAL CANCER; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG TARGETING; ENDOTHELIUM CELL; EPISTAXIS; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HEAD AND NECK CANCER; HEADACHE; HEMOPTYSIS; HUMAN; HYPERTENSION; KIDNEY CANCER; KIDNEY CARCINOMA; LEIOMYOSARCOMA; LIVER CANCER; LIVER CELL CARCINOMA; LOW DRUG DOSE; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPHANGIOGENESIS; MELANOMA; METASTASIS; MICROVASCULATURE; MULTIPLE MYELOMA; NAUSEA; NEUROBLASTOMA; NEUROENDOCRINE TUMOR; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEINURIA; REVIEW; SARCOMA; SIDE EFFECT; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; STOMATITIS; THYROID CANCER; TUMOR VASCULARIZATION; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BENZENESULFONATES; HEMATOLOGIC NEOPLASMS; HUMANS; INDOLES; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; PHTHALAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIDINES; PYRROLES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; THALIDOMIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WNT SIGNALING PATHWAY;

EID: 81155126204     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800911798073113     Document Type: Review

References (302)

1. Bergers, G.; Benjamin, L. E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 2003, 3, 401-410.
2. Hicklin, D. J.; Ellis, L. M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 2005, 23, 1011-1027.
3. Ferrara, N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004, 9 (Suppl 1), 2-10.
4. Podar, K.; Richardson, P. G.; Chauhan, D.; Anderson, K. C. Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma. Expert Rev. Anticancer Ther. 2007, 7, 551-566.
5. Dvorak, H. F.; Nagy, J. A.; Dvorak, J. T.; Dvorak, A. M. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am. J. Pathol. 1988, 133, 95-109.
6. Morikawa, S.; Baluk, P.; Kaidoh, T.; Haskell, A.; Jain, R. K.; McDonald, D. M. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am. J. Pathol. 2002, 160, 985-1000.
7. Baish, J. W.; Jain, R. K. Fractals and cancer. Cancer Res. 2000, 60, 3683-3688.
8. Helmlinger, G.; Yuan, F.; Dellian, M.; Jain, R. K. Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat. Med. 1997, 3, 177-182.
9. Vacca, A.; Ria, R.; Semeraro, F.; Merchionne, F.; Coluccia, M.; Boccarelli, A.; Scavelli, C.; Nico, B.; Gernone, A.; Battelli, F.; Tabilio, A.; Guidolin, D.; Petrucci, M. T.; Ribatti, D.; Dammacco, F. Endothelial cells in the bone marrow of patients with multiple myeloma. Blood 2003, 102, 3340-3348.
10. Dankbar, B.; Padro, T.; Leo, R.; Feldmann, B.; Kropff, M.; Mesters, R. M.; Serve, H.; Berdel, W. E.; Kienast, J. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 2000, 95, 2630-2636.
11. Vacca, A.; Ribatti, D.; Presta, M.; Minischetti, M.; Iurlaro, M.; Ria, R.; Albini, A.; Bussolino, F.; Dammacco, F. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999, 93, 3064-3073.
12. Bisping, G.; Leo, R.; Wenning, D.; Dankbar, B.; Padro, T.; Kropff, M.; Scheffold, C.; Kroger, M.; Mesters, R. M.; Berdel, W. E.; Kienast, J. Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma. Blood 2003, 101, 2775-2783.
13. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971, 285, 1182-1186.
14. D'Amato, R. J.; Lentzsch, S.; Anderson, K. C.; Rogers, M. S. Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma. Semin. Oncol. 2001, 28, 597-601.
15. Singhal, S.; Mehta, J.; Desikan, R.; Ayers, D.; Roberson, P.; Eddlemon, P.; Munshi, N.; Anaissie, E.; Wilson, C.; Dhodapkar, M.; Zeddis, J.; Barlogie, B. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 1999, 341, 1565-1571.
16. Nelson, A. R.; Fingleton, B.; Rothenberg, M. L.; Matrisian, L. M. Matrix metalloproteinases: biologic activity and clinical implications. J. Clin. Oncol. 2000, 18, 1135-1149.
17. Nangia-Makker, P.; Honjo, Y.; Sarvis, R.; Akahani, S.; Hogan, V.; Pienta, K. J.; Raz, A. Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am. J. Pathol. 2000, 156, 899-909.
18. Gamble, J.; Meyer, G.; Noack, L.; Furze, J.; Matthias, L.; Kovach, N.; Harlant, J.; Vadas, M. B1 integrin activation inhibits in vitro tube formation: effects on cell migration, vacuole coalescence and lumen formation. Endothelium 1999, 7, 23-34.
19. Yang, S.; Graham, J.; Kahn, J. W.; Schwartz, E. A.; Gerritsen, M. E. Functional roles for PECAM-1 (CD31) and VE-cadherin (CD144) in tube assembly and lumen formation in three-dimensional collagen gels. Am. J. Pathol. 1999, 155, 887-895.
20. Eilken, H. M.; Adams, R. H. Dynamics of endothelial cell behavior in sprouting angiogenesis. Curr. Opin. Cell Biol. 2010, 22, 617-625.
21. Parker, L. H.; Schmidt, M.; Jin, S. W.; Gray, A. M.; Beis, D.; Pham, T.; Frantz, G.; Palmieri, S.; Hillan, K.; Stainier, D. Y.; De Sauvage, F. J.; Ye, W. The endothelial-cell-derived secreted factor Egfl7 regulates vascular tube formation. Nature 2004, 428, 754-758.
22. Holash, J.; Maisonpierre, P. C.; Compton, D.; Boland, P.; Alexander, C. R.; Zagzag, D.; Yancopoulos, G. D.; Wiegand, S. J. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999, 284, 1994-1998.
23. Rafii, S.; Lyden, D.; Benezra, R.; Hattori, K.; Heissig, B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat. Rev. Cancer 2002, 2, 826-835.
24. Folberg, R.; Hendrix, M. J.; Maniotis, A. J. Vasculogenic mimicry and tumor angiogenesis. Am. J. Pathol. 2000, 156, 361-381.
25. Chang, Y. S.; di Tomaso, E.; McDonald, D. M.; Jones, R.; Jain, R. K.; Munn, L. L. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc. Natl. Acad. Sci. U. S. A. 2000, 97, 14608-14613.
26. Yancopoulos, G. D.; Davis, S.; Gale, N. W.; Rudge, J. S.; Wiegand, S. J.; Holash, J. Vascular-specific growth factors and blood vessel formation. Nature 2000, 407, 242-248.
27. Hendrix, M. J.; Seftor, E. A.; Meltzer, P. S.; Gardner, L. M.; Hess, A. R.; Kirschmann, D. A.; Schatteman, G. C.; Seftor, R. E. Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc. Natl. Acad. Sci. U. S. A. 2001, 98, 8018-8023.
28. Folkman, J. Can mosaic tumor vessels facilitate molecular diagnosis of cancer? Proc. Natl. Acad. Sci. U. S. A. 2001, 98, 398-400.
29. Scavelli, C.; Nico, B.; Cirulli, T.; Ria, R.; Di Pietro, G.; Mangieri, D.; Bacigalupo, A.; Mangialardi, G.; Coluccia, A. M.; Caravita, T.; Molica, S.; Ribatti, D.; Dammacco, F.; Vacca, A. Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma. Oncogene 2008, 27, 663-74
30. Chen, H.; Campbell, R. A.; Chang, Y.; Li, M.; Wang, C. S.; Li, J.; Sanchez, E.; Share, M.; Steinberg, J.; Berenson, A.; Shalitin, D.; Zeng, Z.; Gui, D.; Perez-Pinera, P.; Berenson, R. J.; Said, J.; Bonavida, B.; Deuel, T. F.; Berenson, J. R. Pleiotrophin produced by multiple myeloma induces transdifferentiation of monocytes into vascular endothelial cells: a novel mechanism of tumor-induced vasculogenesis. Blood 2009, 113, 1992-2002.
31. Nico, B.; Mangieri, D.; Crivellato, E.; Vacca, A.; Ribatti, D. Mast cells contribute to vasculogenic mimicry in multiple myeloma. Stem Cells Dev. 2008, 17, 19-22.
32. Ria, R.; Piccoli, C.; Cirulli, T.; Falzetti, F.; Mangialardi, G.; Guidolin, D.; Tabilio, A.; Di Renzo, N.; Guarini, A.; Ribatti, D.; Dammacco, F.; Vacca, A. Endothelial differentiation of hematopoietic stem and progenitor cells from patients with multiple myeloma. Clin. Cancer Res. 2008, 14, 1678-1685.
33. Ferrara, N.; Gerber, H. P.; LeCouter, J. The biology of VEGF and its receptors. Nat. Med. 2003, 9, 669-676.
34. Leung, D. W.; Cachianes, G.; Kuang, W. J.; Goeddel, D. V.; Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246, 1306-1309.
35. Houck, K. A.; Ferrara, N.; Winer, J.; Cachianes, G.; Li, B.; Leung, D. W. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol. Endocrinol. 1991, 5, 1806-1814.
36. Tischer, E.; Mitchell, R.; Hartman, T.; Silva, M.; Gospodarowicz, D.; Fiddes, J. C.; Abraham, J. A. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J. Biol. Chem. 1991, 266, 11947-11954.
37. Satoh, H.; Yoshida, M. C.; Matsushime, H.; Shibuya, M.; Sasaki, M. Regional localization of the human c-ros-1 on 6q22 and flt on 13q12. Jpn. J. Cancer Res. 1987, 78, 772-775.
38. de Vries, C.; Escobedo, J. A.; Ueno, H.; Houck, K.; Ferrara, N.; Williams, L. T. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992, 255, 989-991.
39. Shibuya, M.; Yamaguchi, S.; Yamane, A.; Ikeda, T.; Tojo, A.; Matsushime, H.; Sato, M. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 1990, 5, 519-524.
40. Terman, B. I.; Dougher-Vermazen, M.; Carrion, M. E.; Dimitrov, D.; Armellino, D. C.; Gospodarowicz, D.; Bohlen, P. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. Biophys. Res. Commun. 1992, 187, 1579-1586.
41. Quinn, T. P.; Peters, K. G.; De Vries, C.; Ferrara, N.; Williams, L. T. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc. Natl. Acad. Sci. U. S. A. 1993, 90, 7533-7537.
42. Sait, S. N.; Dougher-Vermazen, M.; Shows, T. B.; Terman, B. I. The kinase insert domain receptor gene (KDR) has been relocated to chromosome 4q11-->q12. Cytogenet. Cell Genet. 1995, 70, 145-146.
43. Fong, G. H.; Rossant, J.; Gertsenstein, M.; Breitman, M. L. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995, 376, 66-70.
44. Shalaby, F.; Rossant, J.; Yamaguchi, T. P.; Gertsenstein, M.; Wu, X. F.; Breitman, M. L.; Schuh, A. C. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995, 376, 62-66.
45. Carmeliet, P.; Moons, L.; Luttun, A.; Vincenti, V.; Compernolle, V.; De Mol, M.; Wu, Y.; Bono, F.; Devy, L.; Beck, H.; Scholz, D.; Acker, T.; DiPalma, T.; Dewerchin, M.; Noel, A.; Stalmans, I.; Barra, A.; Blacher, S.; Vandendriessche, T.; Ponten, A.; Eriksson, U.; Plate, K. H.; Foidart, J. M.; Schaper, W.; Charnock-Jones, D. S.; Hicklin, D. J.; Herbert, J. M.; Collen, D.; Persico, M. G. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med. 2001, 7, 575-583.
46. Autiero, M.; Waltenberger, J.; Communi, D.; Kranz, A.; Moons, L.; Lambrechts, D.; Kroll, J.; Plaisance, S.; De Mol, M.; Bono, F.; Kliche, S.; Fellbrich, G.; Ballmer-Hofer, K.; Maglione, D.; Mayr-Beyrle, U.; Dewerchin, M.; Dombrowski, S.; Stanimirovic, D.; Van Hummelen, P.; Dehio, C.; Hicklin, D. J.; Persico, G.; Herbert, J. M.; Communi, D.; Shibuya, M.; Collen, D.; Conway, E. M.; Carmeliet, P. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat. Med. 2003, 9, 936-943.
47. Fischer, C.; Mazzone, M.; Jonckx, B.; Carmeliet, P. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat. Rev. Cancer 2008, 8, 942-956.
48. Podar, K.; Anderson, K. C. The pathophysiological role of VEGF in hematological malignancies: therapeutic implications. Blood 2005, 105, 1383-1395.
49. Fong, G. H.; Zhang, L.; Bryce, D. M.; Peng, J. Increased hemangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice. Development 1999, 126, 3015-3025.
50. Matsumoto, T.; Claesson-Welsh, L. VEGF receptor signal transduction. Sci. STKE 2001, 2001, RE21.
51. Hiratsuka, S.; Minowa, O.; Kuno, J.; Noda, T.; Shibuya, M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc. Natl. Acad. Sci. U. S. A. 1998, 95, 9349-9354.
52. Hattori, K.; Heissig, B.; Wu, Y.; Dias, S.; Tejada, R.; Ferris, B.; Hicklin, D. J.; Zhu, Z.; Bohlen, P.; Witte, L.; Hendrikx, J.; Hackett, N. R.; Crystal, R. G.; Moore, M. A.; Werb, Z.; Lyden, D.; Rafii, S. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat. Med. 2002, 8, 841-849.
53. Gerber, H. P.; Malik, A. K.; Solar, G. P.; Sherman, D.; Liang, X. H.; Meng, G.; Hong, K.; Marsters, J. C.; Ferrara, N. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 2002, 417, 954-958.
54. Clauss, M.; Weich, H.; Breier, G.; Knies, U.; Rockl, W.; Waltenberger, J.; Risau, W. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J. Biol. Chem. 1996, 271, 17629-17634.
55. Sawano, A.; Iwai, S.; Sakurai, Y.; Ito, M.; Shitara, K.; Nakahata, T.; Shibuya, M. Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans. Blood 2001, 97, 785-791.
56. Barleon, B.; Sozzani, S.; Zhou, D.; Weich, H. A.; Mantovani, A.; Marme, D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996, 87, 3336-3343.
57. Luttun, A.; Tjwa, M.; Carmeliet, P. Placental growth factor (PlGF) and its receptor Flt-1 (VEGFR-1): novel therapeutic targets for angiogenic disorders. Ann. N. Y. Acad. Sci. 2002, 979, 80-93.
58. LeCouter, J.; Moritz, D. R.; Li, B.; Phillips, G. L.; Liang, X. H.; Gerber, H. P.; Hillan, K. J.; Ferrara, N. Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science 2003, 299, 890-893.
59. Hiratsuka, S.; Nakamura, K.; Iwai, S.; Murakami, M.; Itoh, T.; Kijima, H.; Shipley, J. M.; Senior, R. M.; Shibuya, M. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2002, 2, 289-300.
60. Kearney, J. B.; Kappas, N. C.; Ellerstrom, C.; DiPaola, F. W.; Bautch, V. L. The VEGF receptor flt-1 (VEGFR-1) is a positive modulator of vascular sprout formation and branching morphogenesis. Blood 2004, 103, 4527-4535.
61. Kappas, N. C.; Zeng, G.; Chappell, J. C.; Kearney, J. B.; Hazarika, S.; Kallianos, K. G.; Patterson, C.; Annex, B. H.; Bautch, V. L. The VEGF receptor Flt-1 spatially modulates Flk-1 signaling and blood vessel branching. J. Cell Biol. 2008, 181, 847-858.
62. Kaplan, R. N.; Riba, R. D.; Zacharoulis, S.; Bramley, A. H.; Vincent, L.; Costa, C.; MacDonald, D. D.; Jin, D. K.; Shido, K.; Kerns, S. A.; Zhu, Z.; Hicklin, D.; Wu, Y.; Port, J. L.; Altorki, N.; Port, E. R.; Ruggero, D.; Shmelkov, S. V.; Jensen, K. K.; Rafii, S.; Lyden, D. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005, 438, 820-827.
63. Schmidt, T.; Kharabi Masouleh, B.; Loges, S.; Cauwenberghs, S.; Fraisl, P.; Maes, C.; Jonckx, B.; De Keersmaecker, K.; Kleppe, M.; Tjwa, M.; Schenk, T.; Vinckier, S.; Fragoso, R.; De Mol, M.; Beel, K.; Dias, S.; Verfaillie, C.; Clark, R. E.; Brummendorf, T. H.; Vandenberghe, P.; Rafii, S.; Holyoake, T.; Hochhaus, A.; Cools, J.; Karin, M.; Carmeliet, G.; Dewerchin, M.; Carmeliet, P. Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemia. Cancer Cell 2011, 19, 740-753.
64. Lohela, M.; Bry, M.; Tammela, T.; Alitalo, K. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr. Opin. Cell Biol. 2009, 21, 154-165.
65. Tammela, T.; Zarkada, G.; Wallgard, E.; Murtomaki, A.; Suchting, S.; Wirzenius, M.; Waltari, M.; Hellstrom, M.; Schomber, T.; Peltonen, R.; Freitas, C.; Duarte, A.; Isoniemi, H.; Laakkonen, P.; Christofori, G.; Yla-Herttuala, S.; Shibuya, M.; Pytowski, B.; Eichmann, A.; Betsholtz, C.; Alitalo, K. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 2008, 454, 656-660.
66. Ria, R.; Roccaro, A. M.; Merchionne, F.; Vacca, A.; Dammacco, F.; Ribatti, D. Vascular endothelial growth factor and its receptors in multiple myeloma. Leukemia 2003, 17, 1961-1966.
67. Sweeney, C. J.; Miller, K. D.; Sissons, S. E.; Nozaki, S.; Heilman, D. K.; Shen, J.; Sledge, G. W. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res. 2001, 61, 3369-3372.
68. Tran, J.; Master, Z.; Yu, J. L.; Rak, J.; Dumont, D. J.; Kerbel, R. S. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc. Natl. Acad. Sci. U. S. A. 2002, 99, 4349-4354.
69. Gabrilovich, D. I.; Chen, H. L.; Girgis, K. R.; Cunningham, H. T.; Meny, G. M.; Nadaf, S.; Kavanaugh, D.; Carbone, D. P. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 1996, 2, 1096-1103.
70. Nakagawa, M.; Kaneda, T.; Arakawa, T.; Morita, S.; Sato, T.; Yomada, T.; Hanada, K.; Kumegawa, M.; Hakeda, Y. Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts. FEBS Lett. 2000, 473, 161-164.
71. Henriksen, K.; Karsdal, M.; Delaisse, J. M.; Engsig, M. T. RANKL and vascular endothelial growth factor (VEGF) induce osteoclast chemotaxis through an ERK1/2-dependent mechanism. J. Biol. Chem. 2003, 278, 48745-48753.
72. Melder, R. J.; Koenig, G. C.; Witwer, B. P.; Safabakhsh, N.; Munn, L. L.; Jain, R. K. During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat. Med. 1996, 2, 992-997.
73. Lyden, D.; Hattori, K.; Dias, S.; Costa, C.; Blaikie, P.; Butros, L.; Chadburn, A.; Heissig, B.; Marks, W.; Witte, L.; Wu, Y.; Hicklin, D.; Zhu, Z.; Hackett, N. R.; Crystal, R. G.; Moore, M. A.; Hajjar, K. A.; Manova, K.; Benezra, R.; Rafii, S. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 2001, 7, 1194-1201.
74. Oosthuyse, B.; Moons, L.; Storkebaum, E.; Beck, H.; Nuyens, D.; Brusselmans, K.; Van Dorpe, J.; Hellings, P.; Gorselink, M.; Heymans, S.; Theilmeier, G.; Dewerchin, M.; Laudenbach, V.; Vermylen, P.; Raat, H.; Acker, T.; Vleminckx, V.; Van Den Bosch, L.; Cashman, N.; Fujisawa, H.; Drost, M. R.; Sciot, R.; Bruyninckx, F.; Hicklin, D. J.; Ince, C.; Gressens, P.; Lupu, F.; Plate, K. H.; Robberecht, W.; Herbert, J. M.; Collen, D.; Carmeliet, P. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat. Genet. 2001, 28, 131-138.
75. Podar, K.; Tai, Y. T.; Davies, F. E.; Lentzsch, S.; Sattler, M.; Hideshima, T.; Lin, B. K.; Gupta, D.; Shima, Y.; Chauhan, D.; Mitsiades, C.; Raje, N.; Richardson, P.; Anderson, K. C. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 2001, 98, 428-435.
76. Podar, K.; Tai, Y. T.; Lin, B. K.; Narsimhan, R. P.; Sattler, M.; Kijima, T.; Salgia, R.; Gupta, D.; Chauhan, D.; Anderson, K. C. Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation. J. Biol. Chem. 2002, 277, 7875-7881.
77. Le Gouill, S.; Podar, K.; Amiot, M.; Hideshima, T.; Chauhan, D.; Itshitsuka, K.; Kumar, S.; Raje, N.; Richardson, P. G.; Harousseau, J. L.; Anderson, K. C. VEGF induces MCL-1 upregulation and protects multiple myeloma cells against apoptosis. Blood 2004, 104, 2886-92
78. Podar, K.; Shringarpure, R.; Tai, Y. T.; Simoncini, M.; Sattler, M.; Ishitsuka, K.; Richardson, P. G.; Hideshima, T.; Chauhan, D.; Anderson, K. C. Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib. Cancer Res. 2004, 64, 7500-7506.
79. Wang, G. L.; Jiang, B. H.; Rue, E. A.; Semenza, G. L. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl. Acad. Sci. U. S. A. 1995, 92, 5510-5514.
80. Iliopoulos, O.; Levy, A. P.; Jiang, C.; Kaelin, W. G.; Goldberg, M. A. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl. Acad. Sci. U. S. A. 1996, 93, 10595-10599.
81. Shweiki, D.; Itin, A.; Soffer, D.; Keshet, E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992, 359, 843-845.
82. Plate, K. H.; Breier, G.; Millauer, B.; Ullrich, A.; Risau, W. Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res. 1993, 53, 5822-5827.
83. Semenza, G. L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 2003, 3, 721-732.
84. Maxwell, P. H.; Wiesener, M. S.; Chang, G. W.; Clifford, S. C.; Vaux, E. C.; Cockman, M. E.; Wykoff, C. C.; Pugh, C. W.; Maher, E. R.; Ratcliffe, P. J. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999, 399, 271-275.
85. Zhong, H.; De Marzo, A. M.; Laughner, E.; Lim, M.; Hilton, D. A.; Zagzag, D.; Buechler, P.; Isaacs, W. B.; Semenza, G. L.; Simons, J. W. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 1999, 59, 5830-5835.
86. Zhang, W.; Tsuchiya, T.; Yasukochi, Y. Transitional change in interaction between HIF-1 and HNF-4 in response to hypoxia. J. Hum. Genet. 1999, 44, 293-299.
87. Siemeister, G.; Weindel, K.; Mohrs, K.; Barleon, B.; Martiny-Baron, G.; Marme, D. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res. 1996, 56, 2299-2301.
88. Zhang, J.; Sattler, M.; Tonon, G.; Grabher, C.; Lababidi, S.; Zimmerhackl, A.; Raab, M. S.; Vallet, S.; Zhou, Y.; Cartron, M. A.; Hideshima, T.; Tai, Y. T.; Chauhan, D.; Anderson, K. C.; Podar, K. Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1alpha-dependent pathway in multiple myeloma. Cancer Res. 2009, 69, 5082-5090.
89. Casanovas, O.; Hicklin, D. J.; Bergers, G.; Hanahan, D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005, 8, 299-309.
90. Carmeliet, P. Angiogenesis in life, disease and medicine. Nature 2005, 438, 932-936.
91. Batchelor, T. T.; Sorensen, A. G.; di Tomaso, E.; Zhang, W. T.; Duda, D. G.; Cohen, K. S.; Kozak, K. R.; Cahill, D. P.; Chen, P. J.; Zhu, M.; Ancukiewicz, M.; Mrugala, M. M.; Plotkin, S.; Drappatz, J.; Louis, D. N.; Ivy, P.; Scadden, D. T.; Benner, T.; Loeffler, J. S.; Wen, P. Y.; Jain, R. K. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11, 83-95.
92. Mizukami, Y.; Jo, W. S.; Duerr, E. M.; Gala, M.; Li, J.; Zhang, X.; Zimmer, M. A.; Iliopoulos, O.; Zukerberg, L. R.; Kohgo, Y.; Lynch, M. P.; Rueda, B. R.; Chung, D. C. Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. Nat. Med. 2005, 11, 992-997.
93. Coluccia, A. M.; Cirulli, T.; Neri, P.; Mangieri, D.; Colanardi, M. C.; Gnoni, A.; Di Renzo, N.; Dammacco, F.; Tassone, P.; Ribatti, D.; Gambacorti-Passerini, C.; Vacca, A. Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib. Blood 2008, 112, 1346-1356.
94. Airoldi, I.; Cocco, C.; Giuliani, N.; Ferrarini, M.; Colla, S.; Ognio, E.; Taverniti, G.; Di Carlo, E.; Cutrona, G.; Perfetti, V.; Rizzoli, V.; Ribatti, D.; Pistoia, V. Constitutive expression of IL-12R beta 2 on human multiple myeloma cells delineates a novel therapeutic target. Blood 2008, 112, 750-759.
95. Dufraine, J.; Funahashi, Y.; Kitajewski, J. Notch signaling regulates tumor angiogenesis by diverse mechanisms. Oncogene 2008, 27, 5132-5137.
96. Noguera-Troise, I.; Daly, C.; Papadopoulos, N. J.; Coetzee, S.; Boland, P.; Gale, N. W.; Lin, H. C.; Yancopoulos, G. D.; Thurston, G. Blockade of Dll4 inhibits tumour growth by promoting nonproductive angiogenesis. Nature 2006, 444, 1032-1037.
97. Noguera-Troise, I.; Daly, C.; Papadopoulos, N. J.; Coetzee, S.; Boland, P.; Gale, N. W.; Lin, H. C.; Yancopoulos, G. D.; Thurston, G. Blockade of Dll4 inhibits tumour growth by promoting nonproductive angiogenesis. Novartis Found. Symp. 2007, 283, 106-120; discussion 121-105, 238-141.
98. Ridgway, J.; Zhang, G.; Wu, Y.; Stawicki, S.; Liang, W. C.; Chanthery, Y.; Kowalski, J.; Watts, R. J.; Callahan, C.; Kasman, I.; Singh, M.; Chien, M.; Tan, C.; Hongo, J. A.; de Sauvage, F.; Plowman, G.; Yan, M. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 2006, 444, 1083-1087.
99. Thurston, G.; Noguera-Troise, I.; Yancopoulos, G. D. The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth. Nat. Rev. Cancer 2007, 7, 327-331.
100. Patel, N. S.; Dobbie, M. S.; Rochester, M.; Steers, G.; Poulsom, R.; Le Monnier, K.; Cranston, D. W.; Li, J. L.; Harris, A. L. Up-regulation of endothelial delta-like 4 expression correlates with vessel maturation in bladder cancer. Clin. Cancer Res. 2006, 12, 4836-4844.
101. Hellstrom, M.; Phng, L. K.; Hofmann, J. J.; Wallgard, E.; Coultas, L.; Lindblom, P.; Alva, J.; Nilsson, A. K.; Karlsson, L.; Gaiano, N.; Yoon, K.; Rossant, J.; Iruela-Arispe, M. L.; Kalen, M.; Gerhardt, H.; Betsholtz, C. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 2007, 445, 776-780.
102. Hofmann, J. J.; Iruela-Arispe, M. L. Notch signaling in blood vessels: who is talking to whom about what? Circ. Res. 2007, 100, 1556-1568.
103. Li, J. L.; Sainson, R. C.; Shi, W.; Leek, R.; Harrington, L. S.; Preusser, M.; Biswas, S.; Turley, H.; Heikamp, E.; Hainfellner, J. A.; Harris, A. L. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Cancer Res. 2007, 67, 11244-11253.
104. Phng, L. K.; Potente, M.; Leslie, J. D.; Babbage, J.; Nyqvist, D.; Lobov, I.; Ondr, J. K.; Rao, S.; Lang, R. A.; Thurston, G.; Gerhardt, H. Nrarp coordinates endothelial Notch and Wnt signaling to control vessel density in angiogenesis. Dev. Cell 2009, 16, 70-82.
105. Scehnet, J. S.; Jiang, W.; Kumar, S. R.; Krasnoperov, V.; Trindade, A.; Benedito, R.; Djokovic, D.; Borges, C.; Ley, E. J.; Duarte, A.; Gill, P. S. Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion. Blood 2007, 109, 4753-4760.
106. Zimrin, A. B.; Pepper, M. S.; McMahon, G. A.; Nguyen, F.; Montesano, R.; Maciag, T. An antisense oligonucleotide to the notch ligand jagged enhances fibroblast growth factor-induced angiogenesis in vitro. J. Biol. Chem. 1996, 271, 32499-32502.
107. Funahashi, Y.; Hernandez, S. L.; Das, I.; Ahn, A.; Huang, J.; Vorontchikhina, M.; Sharma, A.; Kanamaru, E.; Borisenko, V.; Desilva, D. M.; Suzuki, A.; Wang, X.; Shawber, C. J.; Kandel, J. J.; Yamashiro, D. J.; Kitajewski, J. A notch1 ectodomain construct inhibits endothelial notch signaling, tumor growth, and angiogenesis. Cancer Res. 2008, 68, 4727-4735.
108. Li, J. L.; Sainson, R. C.; Oon, C. E.; Turley, H.; Leek, R.; Sheldon, H.; Bridges, E.; Shi, W.; Snell, C.; Bowden, E. T.; Wu, H.; Chowdhury, P. S.; Russell, A. J.; Montgomery, C. P.; Poulsom, R.; Harris, A. L. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Cancer Res. 2011 [Epub ahead of print]
109. Vacca, A.; Ribatti, D.; Roncali, L.; Ranieri, G.; Serio, G.; Silvestris, F.; Dammacco, F. Bone marrow angiogenesis and progression in multiple myeloma. Br. J. Haematol. 1994, 87, 503-508.
110. Sezer, O.; Niemoller, K.; Eucker, J.; Jakob, C.; Kaufmann, O.; Zavrski, I.; Dietel, M.; Possinger, K. Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma. Ann. Hematol. 2000, 79, 574-577.
111. Rajkumar, S. V.; Leong, T.; Roche, P. C.; Fonseca, R.; Dispenzieri, A.; Lacy, M. Q.; Lust, J. A.; Witzig, T. E.; Kyle, R. A.; Gertz, M. A.; Greipp, P. R. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin. Cancer Res. 2000, 6, 3111-3116.
112. Kumar, S.; Fonseca, R.; Dispenzieri, A.; Lacy, M. Q.; Lust, J. A.; Wellik, L.; Witzig, T. E.; Gertz, M. A.; Kyle, R. A.; Greipp, P. R.; Rajkumar, S. V. Prognostic value of angiogenesis in solitary bone plasmacytoma. Blood 2003, 101, 1715-1717.
113. Bhatti, S. S.; Kumar, L.; Dinda, A. K.; Dawar, R. Prognostic value of bone marrow angiogenesis in multiple myeloma: use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological, and laboratory parameters. Am. J. Hematol. 2006, 81, 649-656.
114. Ruoslahti, E. Specialization of tumour vasculature. Nat. Rev. Cancer 2002, 2, 83-90.
115. St Croix, B.; Man, S.; Kerbel, R. S. Reversal of intrinsic and acquired forms of drug resistance by hyaluronidase treatment of solid tumors. Cancer Lett. 1998, 131, 35-44.
116. Pellegrino, A.; Ria, R.; Pietro, G. D.; Cirulli, T.; Surico, G.; Pennisi, A.; Morabito, F.; Ribatti, D.; Vacca, A. Bone marrow endothelial cells in multiple myeloma secrete CXC-chemokines that mediate interactions with plasma cells. Br. J. Haematol. 2005, 129, 248-256.
117. Mangieri, D.; Nico, B.; Benagiano, V.; De Giorgis, M.; Vacca, A.; Ribatti, D. Angiogenic activity of multiple myeloma endothelial cells in vivo in the chick embryo chorioallantoic membrane assay is associated to a down-regulation in the expression of endogenous endostatin. J. Cell Mol. Med. 2008, 12, 1023-1028.
118. Ria, R.; Todoerti, K.; Berardi, S.; Coluccia, A. M.; De Luisi, A.; Mattioli, M.; Ronchetti, D.; Morabito, F.; Guarini, A.; Petrucci, M. T.; Dammacco, F.; Ribatti, D.; Neri, A.; Vacca, A. Gene expression profiling of bone marrow endothelial cells in patients with multiple myeloma. Clin. Cancer Res. 2009, 15, 5369-5378.
119. Streubel, B.; Chott, A.; Huber, D.; Exner, M.; Jager, U.; Wagner, O.; Schwarzinger, I. Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N. Engl. J. Med. 2004, 351, 250-259.
120. Streubel, B.; Drach, J.; Huber, D.; Exner, M.; Esterbauer, H.; Jager, U.; Chott, A.; Schwarzinger, I.; Wagner, O. Bone marrow microvessel endothelial cells in multiple myeloma harbor myeloma-associated chromosomal translocations. Haematologica 2005, 90, 54.
121. D'Amato, R. J.; Loughnan, M. S.; Flynn, E.; Folkman, J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 1994, 91, 4082-4085.
122. Bartlett, J. B.; Dredge, K.; Dalgleish, A. G. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat. Rev. Cancer 2004, 4, 314-322.
123. Hideshima, T.; Chauhan, D.; Shima, Y.; Raje, N.; Davies, F. E.; Tai, Y. T.; Treon, S. P.; Lin, B.; Schlossman, R. L.; Richardson, P.; Muller, G.; Stirling, D. I.; Anderson, K. C. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000, 96, 2943-2950.
124. Yabu, T.; Tomimoto, H.; Taguchi, Y.; Yamaoka, S.; Igarashi, Y.; Okazaki, T. Thalidomide-induced anti-angiogenic action is mediated by ceramide through depletion of VEGF receptors, and antagonized by sphingosine-1-phosphate. Blood 2005, 106, 125-34.
125. Davies, F. E.; Raje, N.; Hideshima, T.; Lentzsch, S.; Young, G.; Tai, Y. T.; Lin, B.; Podar, K.; Gupta, D.; Chauhan, D.; Treon, S. P.; Richardson, P. G.; Schlossman, R. L.; Morgan, G. J.; Muller, G. W.; Stirling, D. I.; Anderson, K. C. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001, 98, 210-216.
126. Merville, P.; Rousset, F.; Banchereau, J.; Klein, B.; Betaille, R. Serum interleukin 10 in early stage multiple myeloma. Lancet 1992, 340, 1544-1545.
127. Shaffer, A. L.; Emre, N. C.; Lamy, L.; Ngo, V. N.; Wright, G.; Xiao, W.; Powell, J.; Dave, S.; Yu, X.; Zhao, H.; Zeng, Y.; Chen, B.; Epstein, J.; Staudt, L. M. IRF4 addiction in multiple myeloma. Nature 2008, 454, 226-31
128. Li, S.; Pal, R.; Monaghan, S. A.; Schafer, P.; Ouyang, H.; Mapara, M.; Galson, D. L.; Lentzsch, S. IMiD immunomodulatory compounds block C/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM. Blood 2011, 117, 5157-5165.
129. Lopez-Girona, A.; Heintel, D.; Zhang, L. H.; Mendy, D.; Gaidarova, S.; Brady, H.; Bartlett, J. B.; Schafer, P. H.; Schreder, M.; Bolomsky, A.; Hilgarth, B.; Zojer, N.; Gisslinger, H.; Ludwig, H.; Daniel, T.; Jager, U.; Chopra, R. Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response. Br. J. Haematol. 2011, 154, 325-336.
130. Richardson, P. G.; Schlossman, R. L.; Weller, E.; Hideshima, T.; Mitsiades, C.; Davies, F.; LeBlanc, R.; Catley, L. P.; Doss, D.; Kelly, K.; McKenney, M.; Mechlowicz, J.; Freeman, A.; Deocampo, R.; Rich, R.; Ryoo, J. J.; Chauhan, D.; Balinski, K.; Zeldis, J.; Anderson, K. C. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002, 100, 3063-3067.
131. Schey, S. A.; Fields, P.; Bartlett, J. B.; Clarke, I. A.; Ashan, G.; Knight, R. D.; Streetly, M.; Dalgleish, A. G. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J. Clin. Oncol. 2004, 22, 3269-3276.
132. Lacy, M. Q.; Hayman, S. R.; Gertz, M. A.; Dispenzieri, A.; Buadi, F.; Kumar, S.; Greipp, P. R.; Lust, J. A.; Russell, S. J.; Dingli, D.; Kyle, R. A.; Fonseca, R.; Bergsagel, P. L.; Roy, V.; Mikhael, J. R.; Stewart, A. K.; Laumann, K.; Allred, J. B.; Mandrekar, S. J.; Rajkumar, S. V. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J. Clin. Oncol. 2009, 27, 5008-5014.
133. Willett, C. G.; Duda, D. G.; di Tomaso, E.; Boucher, Y.; Ancukiewicz, M.; Sahani, D. V.; Lahdenranta, J.; Chung, D. C.; Fischman, A. J.; Lauwers, G. Y.; Shellito, P.; Czito, B. G.; Wong, T. Z.; Paulson, E.; Poleski, M.; Vujaskovic, Z.; Bentley, R.; Chen, H. X.; Clark, J. W.; Jain, R. K. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J. Clin. Oncol. 2009, 27, 3020-3026.
134. Gerber, H. P.; Ferrara, N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 2005, 65, 671-680.
135. Jain, R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307, 58-62.
136. Jain, R. K. Antiangiogenic therapy for cancer: current and emerging concepts. Oncology (Williston Park) 2005, 19, 7-16.
137. Kabbinavar, F. F.; Schulz, J.; McCleod, M.; Patel, T.; Hamm, J. T.; Hecht, J. R.; Mass, R.; Perrou, B.; Nelson, B.; Novotny, W. F. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J. Clin. Oncol. 2005, 23, 3697-3705.
138. Tebbutt, N. C.; Wilson, K.; Gebski, V. J.; Cummins, M. M.; Zannino, D.; van Hazel, G. A.; Robinson, B.; Broad, A.; Ganju, V.; Ackland, S. P.; Forgeson, G.; Cunningham, D.; Saunders, M. P.; Stockler, M. R.; Chua, Y.; Zalcberg, J. R.; Simes, R. J.; Price, T. J. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J. Clin. Oncol. 2011, 28, 3191-3198.
139. Sandler, A.; Gray, R.; Perry, M. C.; Brahmer, J.; Schiller, J. H.; Dowlati, A.; Lilenbaum, R.; Johnson, D. H. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 2006, 355, 2542-2550.
140. Bukowski, R. M.; Yasothan, U.; Kirkpatrick, P. Pazopanib. Nat. Rev. Drug Discov. 2009, 9, 17-18.
141. Yang, J. C.; Haworth, L.; Sherry, R. M.; Hwu, P.; Schwartzentruber, D. J.; Topalian, S. L.; Steinberg, S. M.; Chen, H. X.; Rosenberg, S. A. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 2003, 349, 427-434.
142. Spigel, D. R.; Townley, P. M.; Waterhouse, D. M.; Fang, L.; Adiguzel, I.; Huang, J. E.; Karlin, D. A.; Faoro, L.; Scappaticci, F. A.; Socinski, M. A. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. J. Clin. Oncol. 2011, 29, 2215-2222.
143. Kamba, T.; McDonald, D. M. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br. J. Cancer 2007, 96, 1788-1795.
144. Holash, J.; Davis, S.; Papadopoulos, N.; Croll, S. D.; Ho, L.; Russell, M.; Boland, P.; Leidich, R.; Hylton, D.; Burova, E.; Ioffe, E.; Huang, T.; Radziejewski, C.; Bailey, K.; Fandl, J. P.; Daly, T.; Wiegand, S. J.; Yancopoulos, G. D.; Rudge, J. S. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. U. S. A. 2002, 99, 11393-11398.
145. Chu, Q. S. Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors. Expert. Opin. Biol. Ther. 2009, 9, 263-271.
146. Kim, E. S.; Serur, A.; Huang, J.; Manley, C. A.; McCrudden, K. W.; Frischer, J. S.; Soffer, S. Z.; Ring, L.; New, T.; Zabski, S.; Rudge, J. S.; Holash, J.; Yancopoulos, G. D.; Kandel, J. J.; Yamashiro, D. J. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc. Natl. Acad. Sci. U. S. A. 2002, 99, 11399-11404.
147. Jayson, G. C.; Zweit, J.; Jackson, A.; Mulatero, C.; Julyan, P.; Ranson, M.; Broughton, L.; Wagstaff, J.; Hakannson, L.; Groenewegen, G.; Bailey, J.; Smith, N.; Hastings, D.; Lawrance, J.; Haroon, H.; Ward, T.; McGown, A. T.; Tang, M.; Levitt, D.; Marreaud, S.; Lehmann, F. F.; Herold, M.; Zwierzina, H. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J. Natl. Cancer Inst. 2002, 94, 1484-1493.
148. Jayson, G. C.; Mulatero, C.; Ranson, M.; Zweit, J.; Jackson, A.; Broughton, L.; Wagstaff, J.; Hakansson, L.; Groenewegen, G.; Lawrance, J.; Tang, M.; Wauk, L.; Levitt, D.; Marreaud, S.; Lehmann, F. F.; Herold, M.; Zwierzina, H. Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer. Eur. J. Cancer 2005, 41, 555-563.
149. Wu, Y.; Zhong, Z.; Huber, J.; Bassi, R.; Finnerty, B.; Corcoran, E.; Li, H.; Navarro, E.; Balderes, P.; Jimenez, X.; Koo, H.; Mangalampalli, V. R.; Ludwig, D. L.; Tonra, J. R.; Hicklin, D. J. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer. Clin. Cancer Res. 2006, 12, 6573-6584.
150. Krupitskaya, Y.; Wakelee, H. A. Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer. Curr. Opin. Investig. Drugs 2009, 10, 597-605.
151. Mackey, J.; Gelmon, K.; Martin, M.; McCarthy, N.; Pinter, T.; Rupin, M.; Youssoufian, H. TRIO-012: a multicenter, multinational, randomized, double-blind phase III study of IMC-1121B plus docetaxel versus placebo plus docetaxel in previously untreated patients with HER2-negative, unresectable, locally recurrent or metastatic breast cancer. Clin. Breast Cancer 2009, 9, 258-261.
152. Lowinger, T. B.; Riedl, B.; Dumas, J.; Smith, R. A. Design and discovery of small molecules targeting raf-1 kinase. Curr. Pharm. Des. 2002, 8, 2269-2278.
153. Richly, H.; Kupsch, P.; Passage, K.; Grubert, M.; Hilger, R. A.; Kredtke, S.; Voliotis, D.; Scheulen, M. E.; Seeber, S.; Strumberg, D. A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors. Int. J. Clin. Pharmacol. Ther. 2003, 41, 620-621.
154. O'Farrell, A. M.; Abrams, T. J.; Yuen, H. A.; Ngai, T. J.; Louie, S. G.; Yee, K. W.; Wong, L. M.; Hong, W.; Lee, L. B.; Town, A.; Smolich, B. D.; Manning, W. C.; Murray, L. J.; Heinrich, M. C.; Cherrington, J. M. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003, 101, 3597-3605.
155. Motzer, R. J.; Hudes, G. R.; Curti, B. D.; McDermott, D. F.; Escudier, B. J.; Negrier, S.; Duclos, B.; Moore, L.; O'Toole, T.; Boni, J. P.; Dutcher, J. P. Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma. J. Clin. Oncol. 2007, 25, 3958-3964.
156. Motzer, R. J.; Hutson, T. E.; Tomczak, P.; Michaelson, M. D.; Bukowski, R. M.; Oudard, S.; Negrier, S.; Szczylik, C.; Pili, R.; Bjarnason, G. A.; Garcia-del-Muro, X.; Sosman, J. A.; Solska, E.; Wilding, G.; Thompson, J. A.; Kim, S. T.; Chen, I.; Huang, X.; Figlin, R. A. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2009, 27, 3584-3590.
157. George, S.; Merriam, P.; Maki, R. G.; Van den Abbeele, A. D.; Yap, J. T.; Akhurst, T.; Harmon, D. C.; Bhuchar, G.; O'Mara, M. M.; D'Adamo, D. R.; Morgan, J.; Schwartz, G. K.; Wagner, A. J.; Butrynski, J. E.; Demetri, G. D.; Keohan, M. L. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J. Clin. Oncol. 2009, 27, 3154-3160.
158. Ramakrishnan, V.; Timm, M.; Haug, J. L.; Kimlinger, T. K.; Wellik, L. E.; Witzig, T. E.; Rajkumar, S. V.; Adjei, A. A.; Kumar, S. Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs. Oncogene 2010, 29, 1190-1202.
159. Wood, J. M.; Bold, G.; Buchdunger, E.; Cozens, R.; Ferrari, S.; Frei, J.; Hofmann, F.; Mestan, J.; Mett, H.; O'Reilly, T.; Persohn, E.; Rosel, J.; Schnell, C.; Stover, D.; Theuer, A.; Towbin, H.; Wenger, F.; Woods-Cook, K.; Menrad, A.; Siemeister, G.; Schirner, M.; Thierauch, K. H.; Schneider, M. R.; Drevs, J.; Martiny-Baron, G.; Totzke, F. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 2000, 60, 2178-2189.
160. Thomas, A. L.; Morgan, B.; Drevs, J.; Unger, C.; Wiedenmann, B.; Vanhoefer, U.; Laurent, D.; Dugan, M.; Steward, W. P. Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584. Semin. Oncol. 2003, 30, 32-38.
161. Los, M.; Roodhart, J. M.; Voest, E. E. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist 2007, 12, 443-450.
162. Scott, E. N.; Meinhardt, G.; Jacques, C.; Laurent, D.; Thomas, A. L. Vatalanib: the clinical development of a tyrosine kinase inhibitor of angiogenesis in solid tumours. Expert Opin. Investig. Drugs 2007, 16, 367-379.
163. Lin, B.; Podar, K.; Gupta, D.; Tai, Y. T.; Li, S.; Weller, E.; Hideshima, T.; Lentzsch, S.; Davies, F.; Li, C.; Weisberg, E.; Schlossman, R. L.; Richardson, P. G.; Griffin, J. D.; Wood, J.; Munshi, N. C.; Anderson, K. C. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 2002, 62, 5019-5026.
164. Vij, R.; Ansstas, G.; Mosley, J. C.; Bryant, G.; Hassan, A.; Amador-Ortiz, C.; Procknow, E. Efficacy and tolerability of PTK787/ZK 222584 in a phase II study of post-transplant maintenance therapy in patients with multiple myeloma following high-dose chemotherapy and autologous stem cell transplant. Leuk. Lymphoma 2010, 51, 1577-1579.
165. Kumar, R.; Knick, V. B.; Rudolph, S. K.; Johnson, J. H.; Crosby, R. M.; Hopper, T. M.; Miller, C. G.; Harrington, L. E.; Onori, J. A.; Mullin, R. J.; Gilmer, T. M.; Truesdale, A. T.; Epperly, A. H.; Bolor, A.; Cheung, M.; Stafford, J. A.; Luttrell, D. K. GW786034: a pan-Inhibitor of VEGF receptors with potent anti-tumor and anti-angiogenic activity. AACR-NCI-EORTC International Conference -Molecular Targets and Cancer Therapeutics 2005, 58-59.
166. Glaxo SmithKline. Pazopanib Hydrochloride. Pharmacopeial Forum 2006, 32, 217.
167. Sternberg, C. N.; Szczylik, C.; Lee, E.; Salman, P. V.; Mardiak, J.; Davis, I. D.; Pandite, L.; Chen, M.; McCann, L.; Hawkins, R. A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). J. Clin. Oncol. 2009, 27:15s, 2009 (suppl; abstr 5021),
168. Hutson, T. E.; Davis, I. D.; Machiels, J. P.; De Souza, P. L.; Rottey, S.; Hong, B. F.; Epstein, R. J.; Baker, K. L.; McCann, L.; Crofts, T.; Pandite, L.; Figlin, R. A. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2010, 28, 1061-8
169. Hurwitz, H.; Dowlati, A.; Savage, S.; Fernando, N.; Lasalvia, S.; Whitehead, B.; Suttle, B.; Collins, D.; Ho, P.; Pandite, L. Safety, tolerability and pharmacokinetics of oral administration of GW786034 in pts with solid tumors. J. Clin. Oncol. 2005, 23, 3012.
170. Sloan, B.; Scheinfeld, N. S. Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy. Curr. Opin. Investig. Drugs 2008, 9, 1324-1335.
171. Podar, K.; Tonon, G.; Sattler, M.; Tai, Y. T.; Legouill, S.; Yasui, H.; Ishitsuka, K.; Kumar, S.; Kumar, R.; Pandite, L. N.; Hideshima, T.; Chauhan, D.; Anderson, K. C. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 19478-83
172. Prince, H. M.; Honemann, D.; Spencer, A.; Rizzieri, D. A.; Stadtmauer, E. A.; Roberts, A. W.; Bahlis, N.; Tricot, G.; Bell, B.; Demarini, D. J.; Benjamin Suttle, A.; Baker, K. L.; Pandite, L. N. Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034). Blood 2009, 113, 4819-4820.
173. Kelly, R. J.; Rixe, O. Axitinib--a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor. Target Oncol. 2009, 4, 297-305.
174. Rugo, H. S.; Herbst, R. S.; Liu, G.; Park, J. W.; Kies, M. S.; Steinfeldt, H. M.; Pithavala, Y. K.; Reich, S. D.; Freddo, J. L.; Wilding, G. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J. Clin. Oncol. 2005, 23, 5474-5483.
175. Rini, B. I.; Wilding, G.; Hudes, G.; Stadler, W. M.; Kim, S.; Tarazi, J.; Rosbrook, B.; Trask, P. C.; Wood, L.; Dutcher, J. P. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J. Clin. Oncol. 2009, 27, 4462-4468.
176. Schiller, J. H.; Larson, T.; Ou, S. H.; Limentani, S.; Sandler, A.; Vokes, E.; Kim, S.; Liau, K.; Bycott, P.; Olszanski, A. J.; von Pawel, J. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. J. Clin. Oncol. 2009, 27, 3836-3841.
177. Rugo, H. S.; Stopeck, A. T.; Joy, A. A.; Chan, S.; Verma, S.; Lluch, A.; Liau, K. F.; Kim, S.; Bycott, P.; Rosbrook, B.; Bair, A. H.; Soulieres, D. Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer. J. Clin. Oncol. 2011, 29, 2459-2465.
178. Spano, J. P.; Chodkiewicz, C.; Maurel, J.; Wong, R.; Wasan, H.; Barone, C.; Letourneau, R.; Bajetta, E.; Pithavala, Y.; Bycott, P.; Trask, P.; Liau, K.; Ricart, A. D.; Kim, S.; Rixe, O. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet 2008, 371, 2101-2108.
179. Ciardiello, F.; Tortora, G. EGFR antagonists in cancer treatment. N. Engl. J. Med. 2008, 358, 1160-1174.
180. Bates, D. ZD-6474. AstraZeneca. Curr. Opin. Investig. Drugs 2003, 4, 1468-1472.
181. Natale, R. B.; Bodkin, D.; Govindan, R.; Sleckman, B. G.; Rizvi, N. A.; Capo, A.; Germonpre, P.; Eberhardt, W. E.; Stockman, P. K.; Kennedy, S. J.; Ranson, M. Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study. J. Clin. Oncol. 2009, 27, 2523-2529.
182. Hanrahan, E. O.; Lin, H. Y.; Kim, E. S.; Yan, S.; Du, D. Z.; McKee, K. S.; Tran, H. T.; Lee, J. J.; Ryan, A. J.; Langmuir, P.; Johnson, B. E.; Heymach, J. V. Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for Vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J. Clin. Oncol. 2010, 28, 193-201
183. Hanrahan, E. O.; Ryan, A. J.; Mann, H.; Kennedy, S. J.; Langmuir, P.; Natale, R. B.; Herbst, R. S.; Johnson, B. E.; Heymach, J. V. Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clin. Cancer Res. 2009, 15, 3600-3609.
184. Miller, K. D.; Trigo, J. M.; Wheeler, C.; Barge, A.; Rowbottom, J.; Sledge, G.; Baselga, J. A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin. Cancer Res. 2005, 11, 3369-3376.
185. Kovacs, M. J.; Reece, D. E.; Marcellus, D.; Meyer, R. M.; Mathews, S.; Dong, R. P.; Eisenhauer, E. A phase II study of ZD6474 (Zactima, a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma--NCIC CTG IND.145. Invest. New Drugs 2006, 24, 529-535.
186. Graff, J. R.; McNulty, A. M.; Hanna, K. R.; Konicek, B. W.; Lynch, R. L.; Bailey, S. N.; Banks, C.; Capen, A.; Goode, R.; Lewis, J. E.; Sams, L.; Huss, K. L.; Campbell, R. M.; Iversen, P. W.; Neubauer, B. L.; Brown, T. J.; Musib, L.; Geeganage, S.; Thornton, D. The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res. 2005, 65, 7462-7469.
187. Keyes, K.; Cox, K.; Treadway, P.; Mann, L.; Shih, C.; Faul, M. M.; Teicher, B. A. An in vitro tumor model: analysis of angiogenic factor expression after chemotherapy. Cancer Res. 2002, 62, 5597-5602.
188. Keyes, K. A.; Mann, L.; Sherman, M.; Galbreath, E.; Schirtzinger, L.; Ballard, D.; Chen, Y. F.; Iversen, P.; Teicher, B. A. LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice. Cancer Chemother. Pharmacol. 2004, 53, 133-140.
189. Herbst, R. S. Targeted therapy using novel agents in the treatment of non-small-cell lung cancer. Clin. Lung Cancer 2002, 3(Suppl 1), S30-38.
190. Podar, K.; Raab, M. S.; Chauhan, D.; Anderson, K. C. The therapeutic role of targeting protein kinase C in solid and hematologic malignancies. Expert Opin. Investig. Drugs 2007, 16, 1693-1707.
191. Podar, K.; Raab, M. S.; Zhang, J.; McMillin, D.; Breitkreutz, I.; Tai, Y. T.; Lin, B. K.; Munshi, N.; Hideshima, T.; Chauhan, D.; Anderson, K. C. Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl). Blood 2007, 109, 1669-1677.
192. O'Farrell, A. M.; Yuen, H. A.; Smolich, B.; Hannah, A. L.; Louie, S. G.; Hong, W.; Stopeck, A. T.; Silverman, L. R.; Lancet, J. E.; Karp, J. E.; Albitar, M.; Cherrington, J. M.; Giles, F. J. Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia. Leuk. Res. 2004, 28, 679-689.
193. Giles, F. J.; Stopeck, A. T.; Silverman, L. R.; Lancet, J. E.; Cooper, M. A.; Hannah, A. L.; Cherrington, J. M.; O'Farrell, A. M.; Yuen, H. A.; Louie, S. G.; Hong, W.; Cortes, J. E.; Verstovsek, S.; Albitar, M.; O'Brien, S. M.; Kantarjian, H. M.; Karp, J. E. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood 2003, 102, 795-801.
194. Fiedler, W.; Mesters, R.; Tinnefeld, H.; Loges, S.; Staib, P.; Duhrsen, U.; Flasshove, M.; Ottmann, O. G.; Jung, W.; Cavalli, F.; Kuse, R.; Thomalla, J.; Serve, H.; O'Farrell, A. M.; Jacobs, M.; Brega, N. M.; Scigalla, P.; Hossfeld, D. K.; Berdel, W. E. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood 2003, 102, 2763-2767.
195. Beebe, J. S.; Jani, J. P.; Knauth, E.; Goodwin, P.; Higdon, C.; Rossi, A. M.; Emerson, E.; Finkelstein, M.; Floyd, E.; Harriman, S.; Atherton, J.; Hillerman, S.; Soderstrom, C.; Kou, K.; Gant, T.; Noe, M. C.; Foster, B.; Rastinejad, F.; Marx, M. A.; Schaeffer, T.; Whalen, P. M.; Roberts, W. G. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy. Cancer Res. 2003, 63, 7301-7309.
196. Hilberg, F.; Roth, G. J.; Krssak, M.; Kautschitsch, S.; Sommergruber, W.; Tontsch-Grunt, U.; Garin-Chesa, P.; Bader, G.; Zoephel, A.; Quant, J.; Heckel, A.; Rettig, W. J. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008, 68, 4774-4782.
197. Roth, G. J.; Heckel, A.; Colbatzky, F.; Handschuh, S.; Kley, J.; Lehmann-Lintz, T.; Lotz, R.; Tontsch-Grunt, U.; Walter, R.; Hilberg, F. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120). J. Med. Chem. 2009, 52, 4466-4480.
198. Huynh, H.; Ngo, V. C.; Fargnoli, J.; Ayers, M.; Soo, K. C.; Koong, H. N.; Thng, C. H.; Ong, H. S.; Chung, A.; Chow, P.; Pollock, P.; Byron, S.; Tran, E. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin. Cancer Res. 2008, 14, 6146-6153.
199. MacDonald, T. J.; Taga, T.; Shimada, H.; Tabrizi, P.; Zlokovic, B. V.; Cheresh, D. A.; Laug, W. E. Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist. Neurosurgery 2001, 48, 151-157.
200. Burke, P. A.; DeNardo, S. J.; Miers, L. A.; Lamborn, K. R.; Matzku, S.; DeNardo, G. L. Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res. 2002, 62, 4263-4272.
201. Raguse, J. D.; Gath, H. J.; Bier, J.; Riess, H.; Oettle, H. Cilengitide (EMD 121974) arrests the growth of a heavily pretreated highly vascularised head and neck tumour. Oral Oncol. 2004, 40, 228-230.
202. Nisato, R. E.; Tille, J. C.; Jonczyk, A.; Goodman, S. L.; Pepper, M. S. alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro. Angiogenesis 2003, 6, 105-119.
203. Nawrocki, S. T.; Bruns, C. J.; Harbison, M. T.; Bold, R. J.; Gotsch, B. S.; Abbruzzese, J. L.; Elliott, P.; Adams, J.; McConkey, D. J. Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol. Cancer Ther. 2002, 1, 1243-1253.
204. Oikawa, T.; Sasaki, T.; Nakamura, M.; Shimamura, M.; Tanahashi, N.; Omura, S.; Tanaka, K. The proteasome is involved in angiogenesis. Biochem. Biophys. Res. Commun. 1998, 246, 243-248.
205. LeBlanc, R.; Catley, L. P.; Hideshima, T.; Lentzsch, S.; Mitsiades, C. S.; Mitsiades, N.; Neuberg, D.; Goloubeva, O.; Pien, C. S.; Adams, J.; Gupta, D.; Richardson, P. G.; Munshi, N. C.; Anderson, K. C. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 2002, 62, 4996-5000.
206. Huang, H.; Bhat, A.; Woodnutt, G.; Lappe, R. Targeting the ANGPT-TIE2 pathway in malignancy. Nat. Rev. Cancer 2010, 10, 575-585.
207. Falcon, B. L.; Hashizume, H.; Koumoutsakos, P.; Chou, J.; Bready, J. V.; Coxon, A.; Oliner, J. D.; McDonald, D. M. Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels. Am. J. Pathol. 2009, 175, 2159-2170.
208. Thurston, G.; Rudge, J. S.; Ioffe, E.; Zhou, H.; Ross, L.; Croll, S. D.; Glazer, N.; Holash, J.; McDonald, D. M.; Yancopoulos, G. D. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat. Med. 2000, 6, 460-463.
209. Cao, Y.; Sonveaux, P.; Liu, S.; Zhao, Y.; Mi, J.; Clary, B. M.; Li, C. Y.; Kontos, C. D.; Dewhirst, M. W. Systemic overexpression of angiopoietin-2 promotes tumor microvessel regression and inhibits angiogenesis and tumor growth. Cancer Res. 2007, 67, 3835-3844.
210. Williams, R. Discontinued drugs in 2006: oncology drugs. Expert Opin. Investig. Drugs 2008, 17, 269-283.
211. Neal, J.; Wakelee, H. AMG-386, a selective angiopoietin-1/-2-neutralizing peptibody for the potential treatment of cancer. Curr. Opin. Mol. Ther. 2010, 12, 487-495.
212. Mita, A. C.; Takimoto, C. H.; Mita, M.; Tolcher, A.; Sankhala, K.; Sarantopoulos, J.; Valdivieso, M.; Wood, L.; Rasmussen, E.; Sun, Y. N.; Zhong, Z. D.; Bass, M. B.; Le, N.; LoRusso, P. Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors. Clin. Cancer Res. 2010, 16, 3044-3056.
213. Karlan, B. Y.; Oza, A. M.; Hansen, V. L.; Richardson, G. E.; Provencher, D. M.; Ghatage, P.; Tassoudji, M.; Stepan, D. E.; Weinreich, D. M.; Vergote, I. B. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients (pts) with recurrent ovarian carcinoma. J. Clin. Oncol. 2010, 28, 5000.
214. Suchting, S.; Freitas, C.; le Noble, F.; Benedito, R.; Breant, C.; Duarte, A.; Eichmann, A. The Notch ligand Delta-like 4 negatively regulates endothelial tip cell formation and vessel branching. Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 3225-3230.
215. Hoey, T.; Yen, W. C.; Axelrod, F.; Basi, J.; Donigian, L.; Dylla, S.; Fitch-Bruhns, M.; Lazetic, S.; Park, I. K.; Sato, A.; Satyal, S.; Wang, X.; Clarke, M. F.; Lewicki, J.; Gurney, A. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 2009, 5, 168-177.
216. Zeng, Q.; Li, S.; Chepeha, D. B.; Giordano, T. J.; Li, J.; Zhang, H.; Polverini, P. J.; Nor, J.; Kitajewski, J.; Wang, C. Y. Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. Cancer Cell 2005, 8, 13-23.
217. Wedge, S. R.; Kendrew, J.; Hennequin, L. F.; Valentine, P. J.; Barry, S. T.; Brave, S. R.; Smith, N. R.; James, N. H.; Dukes, M.; Curwen, J. O.; Chester, R.; Jackson, J. A.; Boffey, S. J.; Kilburn, L. L.; Barnett, S.; Richmond, G. H.; Wadsworth, P. F.; Walker, M.; Bigley, A. L.; Taylor, S. T.; Cooper, L.; Beck, S.; Jurgensmeier, J. M.; Ogilvie, D. J. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 2005, 65, 4389-4400.
218. Heckman, C. A.; Holopainen, T.; Wirzenius, M.; Keskitalo, S.; Jeltsch, M.; Yla-Herttuala, S.; Wedge, S. R.; Jurgensmeier, J. M.; Alitalo, K. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res. 2008, 68, 4754-4762.
219. Morelli, M. P.; Brown, A. M.; Pitts, T. M.; Tentler, J. J.; Ciardiello, F.; Ryan, A.; Jurgensmeier, J. M.; Eckhardt, S. G. Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines. Mol. Cancer Ther. 2009, 8, 2546-2558.
220. Gomez-Rivera, F.; Santillan-Gomez, A. A.; Younes, M. N.; Kim, S.; Fooshee, D.; Zhao, M.; Jasser, S. A.; Myers, J. N. The tyrosine kinase inhibitor, AZD2171, inhibits vascular endothelial growth factor receptor signaling and growth of anaplastic thyroid cancer in an orthotopic nude mouse model. Clin. Cancer Res. 2007, 13, 4519-4527.
221. Hanrahan, E. O.; Heymach, J. V. Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer. Clin. Cancer Res. 2007, 13, s4617-4622.
222. Matulonis, U. A.; Berlin, S.; Ivy, P.; Tyburski, K.; Krasner, C.; Zarwan, C.; Berkenblit, A.; Campos, S.; Horowitz, N.; Cannistra, S. A.; Lee, H.; Lee, J.; Roche, M.; Hill, M.; Whalen, C.; Sullivan, L.; Tran, C.; Humphreys, B. D.; Penson, R. T. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J. Clin. Oncol. 2009, 27, 5601-5606.
223. Burton, J. B.; Priceman, S. J.; Sung, J. L.; Brakenhielm, E.; An, D. S.; Pytowski, B.; Alitalo, K.; Wu, L. Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis. Cancer Res. 2008, 68, 7828-7837.
224. Bergers, G.; Hanahan, D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 2008, 8, 592-603.
225. Loges, S.; Schmidt, T.; Carmeliet, P. Antimyeloangiogenic therapy for cancer by inhibiting PlGF. Clin. Cancer Res. 2009, 15, 3648-3653.
226. Van de Veire, S.; Stalmans, I.; Heindryckx, F.; Oura, H.; Tijeras-Raballand, A.; Schmidt, T.; Loges, S.; Albrecht, I.; Jonckx, B.; Vinckier, S.; Van Steenkiste, C.; Tugues, S.; Rolny, C.; De Mol, M.; Dettori, D.; Hainaud, P.; Coenegrachts, L.; Contreres, J. O.; Van Bergen, T.; Cuervo, H.; Xiao, W. H.; Le Henaff, C.; Buysschaert, I.; Kharabi Masouleh, B.; Geerts, A.; Schomber, T.; Bonnin, P.; Lambert, V.; Haustraete, J.; Zacchigna, S.; Rakic, J. M.; Jimenez, W.; Noel, A.; Giacca, M.; Colle, I.; Foidart, J. M.; Tobelem, G.; Morales-Ruiz, M.; Vilar, J.; Maxwell, P.; Vinores, S. A.; Carmeliet, G.; Dewerchin, M.; Claesson-Welsh, L.; Dupuy, E.; Van Vlierberghe, H.; Christofori, G.; Mazzone, M.; Detmar, M.; Collen, D.; Carmeliet, P. Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell 2010, 141, 178-190.
227. Fischer, C.; Jonckx, B.; Mazzone, M.; Zacchigna, S.; Loges, S.; Pattarini, L.; Chorianopoulos, E.; Liesenborghs, L.; Koch, M.; De Mol, M.; Autiero, M.; Wyns, S.; Plaisance, S.; Moons, L.; van Rooijen, N.; Giacca, M.; Stassen, J. M.; Dewerchin, M.; Collen, D.; Carmeliet, P. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007, 131, 463-475.
228. Taylor, A. P.; Rodriguez, M.; Adams, K.; Goldenberg, D. M.; Blumenthal, R. D. Altered tumor vessel maturation and proliferation in placenta growth factor-producing tumors: potential relationship to post-therapy tumor angiogenesis and recurrence. Int. J. Cancer 2003, 105, 158-164.
229. Bais, C.; Wu, X.; Yao, J.; Yang, S.; Crawford, Y.; McCutcheon, K.; Tan, C.; Kolumam, G.; Vernes, J. M.; Eastham-Anderson, J.; Haughney, P.; Kowanetz, M.; Hagenbeek, T.; Kasman, I.; Reslan, H. B.; Ross, J.; Van Bruggen, N.; Carano, R. A.; Meng, Y. J.; Hongo, J. A.; Stephan, J. P.; Shibuya, M.; Ferrara, N. PlGF blockade does not inhibit angiogenesis during primary tumor growth. Cell 2010, 141, 166-177.
230. Jayson, G. C.; Parker, G. J.; Mullamitha, S.; Valle, J. W.; Saunders, M.; Broughton, L.; Lawrance, J.; Carrington, B.; Roberts, C.; Issa, B.; Buckley, D. L.; Cheung, S.; Davies, K.; Watson, Y.; Zinkewich-Peotti, K.; Rolfe, L.; Jackson, A. Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume. J. Clin. Oncol. 2005, 23, 973-981.
231. Lewis, N. L.; Lewis, L. D.; Eder, J. P.; Reddy, N. J.; Guo, F.; Pierce, K. J.; Olszanski, A. J.; Cohen, R. B. Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers. J. Clin. Oncol. 2009, 27, 5262-5269.
232. Michael, M.; Vlahovic, G.; Khamly, K.; Pierce, K. J.; Guo, F.; Olszanski, A. J. Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor. Br. J. Cancer 2010, 103, 1554-1561.
233. Bielenberg, D. R.; Pettaway, C. A.; Takashima, S.; Klagsbrun, M. Neuropilins in neoplasms: expression, regulation, and function. Exp. Cell Res. 2006, 312, 584-593.
234. Neufeld, G.; Kessler, O. The semaphorins: versatile regulators of tumour progression and tumour angiogenesis. Nat. Rev. Cancer 2008, 8, 632-645.
235. Staton, C. A.; Kumar, I.; Reed, M. W.; Brown, N. J. Neuropilins in physiological and pathological angiogenesis. J. Pathol. 2007, 212, 237-248.
236. Gagnon, M. L.; Bielenberg, D. R.; Gechtman, Z.; Miao, H. Q.; Takashima, S.; Soker, S.; Klagsbrun, M. Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: In vivo expression and antitumor activity. Proc. Natl. Acad. Sci. U. S. A. 2000, 97, 2573-2578.
237. Soker, S.; Miao, H. Q.; Nomi, M.; Takashima, S.; Klagsbrun, M. VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding. J. Cell Biochem. 2002, 85, 357-368.
238. Soker, S.; Takashima, S.; Miao, H. Q.; Neufeld, G.; Klagsbrun, M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998, 92, 735-745.
239. Pan, Q.; Chanthery, Y.; Liang, W. C.; Stawicki, S.; Mak, J.; Rathore, N.; Tong, R. K.; Kowalski, J.; Yee, S. F.; Pacheco, G.; Ross, S.; Cheng, Z.; Le Couter, J.; Plowman, G.; Peale, F.; Koch, A. W.; Wu, Y.; Bagri, A.; Tessier-Lavigne, M.; Watts, R. J. Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell 2007, 11, 53-67.
240. Pan, Q.; Chathery, Y.; Wu, Y.; Rathore, N.; Tong, R. K.; Peale, F.; Bagri, A.; Tessier-Lavigne, M.; Koch, A. W.; Watts, R. J. Neuropilin-1 binds to VEGF121 and regulates endothelial cell migration and sprouting. J. Biol. Chem. 2007, 282, 24049-24056.
241. Hong, T. M.; Chen, Y. L.; Wu, Y. Y.; Yuan, A.; Chao, Y. C.; Chung, Y. C.; Wu, M. H.; Yang, S. C.; Pan, S. H.; Shih, J. Y.; Chan, W. K.; Yang, P. C. Targeting neuropilin 1 as an antitumor strategy in lung cancer. Clin. Cancer Res. 2007, 13, 4759-4768.
242. Kaelin, W. G.; Ratcliffe, P. J. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol. Cell 2008, 30, 393-402.
243. Carmeliet, P.; Dor, Y.; Herbert, J. M.; Fukumura, D.; Brusselmans, K.; Dewerchin, M.; Neeman, M.; Bono, F.; Abramovitch, R.; Maxwell, P.; Koch, C. J.; Ratcliffe, P.; Moons, L.; Jain, R. K.; Collen, D.; Keshert, E.; Keshet, E. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998, 394, 485-490.
244. Wu, S.; Nishiyama, N.; Kano, M. R.; Morishita, Y.; Miyazono, K.; Itaka, K.; Chung, U. I.; Kataoka, K. Enhancement of angiogenesis through stabilization of hypoxia-inducible factor-1 by silencing prolyl hydroxylase domain-2 gene. Mol. Ther. 2008, 16, 1227-1234.
245. Mazzone, M.; Dettori, D.; Leite de Oliveira, R.; Loges, S.; Schmidt, T.; Jonckx, B.; Tian, Y. M.; Lanahan, A. A.; Pollard, P.; Ruiz de Almodovar, C.; De Smet, F.; Vinckier, S.; Aragones, J.; Debackere, K.; Luttun, A.; Wyns, S.; Jordan, B.; Pisacane, A.; Gallez, B.; Lampugnani, M. G.; Dejana, E.; Simons, M.; Ratcliffe, P.; Maxwell, P.; Carmeliet, P. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 2009, 136, 839-851.
246. Brokers, N.; Le-Huu, S.; Vogel, S.; Hagos, Y.; Katschinski, D. M.; Kleinschmidt, M. Increased chemoresistance induced by inhibition of HIF-prolyl-hydroxylase domain enzymes. Cancer Sci. 2010, 101, 129-36.
247. Cooney, M. M.; Ortiz, J.; Bukowski, R. M.; Remick, S. C. Novel vascular targeting/disrupting agents: combretastatin A4 phosphate and related compounds. Curr. Oncol. Rep. 2005, 7, 90-95.
248. Cooney, M. M.; van Heeckeren, W.; Bhakta, S.; Ortiz, J.; Remick, S. C. Drug insight: vascular disrupting agents and angiogenesis--novel approaches for drug delivery. Nat. Clin. Pract. Oncol. 2006, 3, 682-692.
249. Klasa, R. J.; List, A. F.; Cheson, B. D. Rational approaches to design of therapeutics targeting molecular markers. Hematology Am. Soc. Hematol. Educ. Program 2001, 443-462.
250. Russell, G. J.; Lacey, E. Inhibition of [3H]mebendazole binding to tubulin by structurally diverse microtubule inhibitors which interact at the colchicine binding site. Biochem. Mol. Biol. Int. 1995, 35, 1153-1159.
251. Woods, J. A.; Hadfield, J. A.; Pettit, G. R.; Fox, B. W.; McGown, A. T. The interaction with tubulin of a series of stilbenes based on combretastatin A-4. Br. J. Cancer 1995, 71, 705-711.
252. Dark, G. G.; Hill, S. A.; Prise, V. E.; Tozer, G. M.; Pettit, G. R.; Chaplin, D. J. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res. 1997, 57, 1829-1834.
253. Vincent, L.; Kermani, P.; Young, L. M.; Cheng, J.; Zhang, F.; Shido, K.; Lam, G.; Bompais-Vincent, H.; Zhu, Z.; Hicklin, D. J.; Bohlen, P.; Chaplin, D. J.; May, C.; Rafii, S. Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J. Clin. Invest. 2005, 115, 2992-3006.
254. Dowlati, A.; Robertson, K.; Cooney, M.; Petros, W. P.; Stratford, M.; Jesberger, J.; Rafie, N.; Overmoyer, B.; Makkar, V.; Stambler, B.; Taylor, A.; Waas, J.; Lewin, J. S.; McCrae, K. R.; Remick, S. C. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res. 2002, 62, 3408-3416.
255. Stevenson, J. P.; Rosen, M.; Sun, W.; Gallagher, M.; Haller, D. G.; Vaughn, D.; Giantonio, B.; Zimmer, R.; Petros, W. P.; Stratford, M.; Chaplin, D.; Young, S. L.; Schnall, M.; O'Dwyer, P. J. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J. Clin. Oncol. 2003, 21, 4428-4438.
256. Bilenker, J. H.; Flaherty, K. T.; Rosen, M.; Davis, L.; Gallagher, M.; Stevenson, J. P.; Sun, W.; Vaughn, D.; Giantonio, B.; Zimmer, R.; Schnall, M.; O'Dwyer, P. J. Phase I trial of combretastatin a-4 phosphate with carboplatin. Clin. Cancer Res. 2005, 11, 1527-1533.
257. Ng, Q. S.; Goh, V.; Carnell, D.; Meer, K.; Padhani, A. R.; Saunders, M. I.; Hoskin, P. J. Tumor antivascular effects of radiotherapy combined with combretastatin a4 phosphate in human non-small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 2007, 67, 1375-1380.
258. Delmonte, A.; Sessa, C. AVE8062: a new combretastatin derivative vascular disrupting agent. Expert Opin. Investig. Drugs 2009, 18, 1541-1548.
259. Zhou, S.; Kestell, P.; Baguley, B. C.; Paxton, J. W. 5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy. Invest. New Drugs 2002, 20, 281-295.
260. McKeage, M. J.; Von Pawel, J.; Reck, M.; Jameson, M. B.; Rosenthal, M. A.; Sullivan, R.; Gibbs, D.; Mainwaring, P. N.; Serke, M.; Lafitte, J. J.; Chouaid, C.; Freitag, L.; Quoix, E. Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Br. J. Cancer 2008, 99, 2006-2012.
261. Lara, P. N.; Douillard, J. Y.; Nakagawa, K.; von Pawel, J.; McKeage, M. J.; Albert, I.; Losonczy, G.; Reck, M.; Heo, D. S.; Fan, X.; Fandi, A.; Scagliotti, G. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J. Clin. Oncol. 2011, 29, 2965-2971.
262. Mita, M. M.; Spear, M. A.; Yee, L. K.; Mita, A. C.; Heath, E. I.; Papadopoulos, K. P.; Federico, K. C.; Reich, S. D.; Romero, O.; Malburg, L.; Pilat, M.; Lloyd, G. K.; Neuteboom, S. T.; Cropp, G.; Ashton, E.; LoRusso, P. M. Phase 1 first-in-human trial of the vascular disrupting agent plinabulin(NPI-2358) in patients with solid tumors or lymphomas. Clin. Cancer Res. 2011, 16, 5892-5899.
263. Singh, A. V.; Bandi, M.; Raje, N.; Richardson, P.; Palladino, M. A.; Chauhan, D.; Anderson, K. C. A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cells. Blood 2011, 117, 5692-5700.
264. Schoffski, P.; Thate, B.; Beutel, G.; Bolte, O.; Otto, D.; Hofmann, M.; Ganser, A.; Jenner, A.; Cheverton, P.; Wanders, J.; Oguma, T.; Atsumi, R.; Satomi, M. Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer. Ann. Oncol. 2004, 15, 671-679.
265. de Jonge, M. J.; van der Gaast, A.; Planting, A. S.; van Doorn, L.; Lems, A.; Boot, I.; Wanders, J.; Satomi, M.; Verweij, J. Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors. Clin. Cancer Res. 2005, 11, 3806-3813.
266. Blakey, D. C.; Westwood, F. R.; Walker, M.; Hughes, G. D.; Davis, P. D.; Ashton, S. E.; Ryan, A. J. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin. Cancer Res. 2002, 8, 1974-1983.
267. Davis, P. D.; Dougherty, G. J.; Blakey, D. C.; Galbraith, S. M.; Tozer, G. M.; Holder, A. L.; Naylor, M. A.; Nolan, J.; Stratford, M. R.; Chaplin, D. J.; Hill, S. A. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res. 2002, 62, 7247-7253.
268. LoRusso, P. M.; Gadgeel, S. M.; Wozniak, A.; Barge, A. J.; Jones, H. K.; DelProposto, Z. S.; DeLuca, P. A.; Evelhoch, J. L.; Boerner, S. A.; Wheeler, C. Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors. Invest. New Drugs 2008, 26, 159-167.
269. Perotti, A.; Sessa, C.; Mancuso, A.; Noberasco, C.; Cresta, S.; Locatelli, A.; Carcangiu, M. L.; Passera, K.; Braghetti, A.; Scaramuzza, D.; Zanaboni, F.; Fasolo, A.; Capri, G.; Miani, M.; Peters, W. P.; Gianni, L. Clinical and pharmacological phase I evaluation of Exherin (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing solid tumours. Ann. Oncol. 2009, 20, 741-745.
270. Cai, S. X. Small molecule vascular disrupting agents: potential new drugs for cancer treatment. Recent Pat. Anticancer Drug Discov. 2007, 2, 79-101.
271. Traynor, A. M.; Gordon, M. S.; Alberti, D.; Mendelson, D. S.; Munsey, M. S.; Wilding, G.; Gammans, R. E.; Read, W. L. A dose escalation, safety, and tolerability study of MN-029 in patients with advanced solid tumors. Invest. New Drugs 2010, 28, 509-15
272. Wood, J.; Scott, E.; Thomas, A. L. Novel VEGF signalling inhibitors: how helpful are biomarkers in their early development? Expert Opin. Investig. Drugs 2009, 18, 1701-1714.
273. Jain, R. K.; Duda, D. G.; Willett, C. G.; Sahani, D. V.; Zhu, A. X.; Loeffler, J. S.; Batchelor, T. T.; Sorensen, A. G. Biomarkers of response and resistance to antiangiogenic therapy. Nat. Rev. Clin. Oncol. 2009, 6, 327-338.
274. Luttun, A.; Tjwa, M.; Moons, L.; Wu, Y.; Angelillo-Scherrer, A.; Liao, F.; Nagy, J. A.; Hooper, A.; Priller, J.; De Klerck, B.; Compernolle, V.; Daci, E.; Bohlen, P.; Dewerchin, M.; Herbert, J. M.; Fava, R.; Matthys, P.; Carmeliet, G.; Collen, D.; Dvorak, H. F.; Hicklin, D. J.; Carmeliet, P. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat. Med. 2002, 8, 831-840.
275. Rafii, S. Circulating endothelial precursors: mystery, reality, and promise. J. Clin. Invest. 2000, 105, 17-19.
276. De Palma, M.; Venneri, M. A.; Galli, R.; Sergi Sergi, L.; Politi, L. S.; Sampaolesi, M.; Naldini, L. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005, 8, 211-226.
277. Gothert, J. R.; Gustin, S. E.; van Eekelen, J. A.; Schmidt, U.; Hall, M. A.; Jane, S. M.; Green, A. R.; Gottgens, B.; Izon, D. J.; Begley, C. G. Genetically tagging endothelial cells in vivo: bone marrow-derived cells do not contribute to tumor endothelium. Blood 2004, 104, 1769-1777.
278. Bertolini, F.; Shaked, Y.; Mancuso, P.; Kerbel, R. S. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat. Rev. Cancer 2006, 6, 835-845.
279. Bertolini, F.; Paul, S.; Mancuso, P.; Monestiroli, S.; Gobbi, A.; Shaked, Y.; Kerbel, R. S. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res. 2003, 63, 4342-4346.
280. Kerbel, R. S.; Kamen, B. A. The anti-angiogenic basis of metronomic chemotherapy. Nat. Rev. Cancer 2004, 4, 423-436.
281. Zhang, H.; Vakil, V.; Braunstein, M.; Smith, E. L.; Maroney, J.; Chen, L.; Dai, K.; Berenson, J. R.; Hussain, M. M.; Klueppelberg, U.; Norin, A. J.; Akman, H. O.; Ozcelik, T.; Batuman, O. A. Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood 2005, 105, 3286-3294.
282. Kerbel, R. S. Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 2006, 312, 1171-1175.
283. Hanahan, D.; Weinberg, R. A. The hallmarks of cancer. Cell 2000, 100, 57-70.
284. Browder, T.; Butterfield, C. E.; Kraling, B. M.; Shi, B.; Marshall, B.; O'Reilly, M. S.; Folkman, J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000, 60, 1878-1886.
285. Gasparini, G. Metronomic scheduling: the future of chemotherapy? Lancet Oncol. 2001, 2, 733-740.
286. Kamen, B. A.; Rubin, E.; Aisner, J.; Glatstein, E. High-time chemotherapy or high time for low dose. J. Clin. Oncol. 2000, 18, 2935-2937.
287. Kerbel, R. S.; Klement, G.; Pritchard, K. I.; Kamen, B. Continuous low-dose anti-angiogenic/ metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann. Oncol. 2002, 13, 12-15.
288. Pietras, K.; Hanahan, D. A multitargeted, metronomic, and maximum-tolerated dose chemo-switch regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J. Clin. Oncol. 2005, 23, 939-952.
289. Du, R.; Lu, K. V.; Petritsch, C.; Liu, P.; Ganss, R.; Passegue, E.; Song, H.; Vandenberg, S.; Johnson, R. S.; Werb, Z.; Bergers, G. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008, 13, 206-220.
290. Lee, S. L.; Rouhi, P.; Dahl Jensen, L.; Zhang, D.; Ji, H.; Hauptmann, G.; Ingham, P.; Cao, Y. Hypoxia-induced pathological angiogenesis mediates tumor cell dissemination, invasion, and metastasis in a zebrafish tumor model. Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 19485-19490.
291. Paez-Ribes, M.; Allen, E.; Hudock, J.; Takeda, T.; Okuyama, H.; Vinals, F.; Inoue, M.; Bergers, G.; Hanahan, D.; Casanovas, O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15, 220-231.
292. Kienast, Y.; von Baumgarten, L.; Fuhrmann, M.; Klinkert, W. E.; Goldbrunner, R.; Herms, J.; Winkler, F. Real-time imaging reveals the single steps of brain metastasis formation. Nat. Med. 2010, 16, 116-22.
293. Yu, J. L.; Rak, J. W.; Coomber, B. L.; Hicklin, D. J.; Kerbel, R. S. Effect of p53 status on tumor response to antiangiogenic therapy. Science 2002, 295, 1526-1528.
294. Hu, X. B.; Feng, F.; Wang, Y. C.; Wang, L.; He, F.; Dou, G. R.; Liang, L.; Zhang, H. W.; Liang, Y. M.; Han, H. Blockade of Notch signaling in tumor-bearing mice may lead to tumor regression, progression, or metastasis, depending on tumor cell types. Neoplasia 2009, 11, 32-38.
295. Benjamin, L. E.; Hemo, I.; Keshet, E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 1998, 125, 1591-1598.
296. Bergers, G.; Song, S.; Meyer-Morse, N.; Bergsland, E.; Hanahan, D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 2003, 111, 1287-1295.
297. Erber, R.; Thurnher, A.; Katsen, A. D.; Groth, G.; Kerger, H.; Hammes, H. P.; Menger, M. D.; Ullrich, A.; Vajkoczy, P. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J. 2004, 18, 338-340.
298. Pollard, J. W. Trophic macrophages in development and disease. Nat. Rev. Immunol. 2009, 9, 259-270.
299. De Palma, M.; Mazzieri, R.; Politi, L. S.; Pucci, F.; Zonari, E.; Sitia, G.; Mazzoleni, S.; Moi, D.; Venneri, M. A.; Indraccolo, S.; Falini, A.; Guidotti, L. G.; Galli, R.; Naldini, L. Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. Cancer Cell 2008, 14, 299-311.
300. Yang, L.; DeBusk, L. M.; Fukuda, K.; Fingleton, B.; Green-Jarvis, B.; Shyr, Y.; Matrisian, L. M.; Carbone, D. P.; Lin, P. C. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004, 6, 409-421.
301. Bunt, S. K.; Sinha, P.; Clements, V. K.; Leips, J.; Ostrand-Rosenberg, S. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J. Immunol. 2006, 176, 284-290.
302. Hurwitz, H.; Fehrenbacher, L.; Novotny, W.; Cartwright, T.; Hainsworth, J.; Heim, W.; Berlin, J.; Baron, A.; Griffing, S.; Holmgren, E.; Ferrara, N.; Fyfe, G.; Rogers, B.; Ross, R.; Kabbinavar, F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004, 350, 2335-2342.